ASLN ASLAN Pharmaceuticals Limited

4
-0.01  -0%
Previous Close 4.01
Open 4
Price To Book 4.21
Market Cap 128199200
Shares 32,049,800
Volume 3,324
Short Ratio
Av. Daily Volume 17,907

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 data due 2H 2019.
Varlitinib - TREETOPP
Biliary tract cancer
Phase 2 trial did not meet primary endpoint - January 13, 2019.
Varlitinib
Gastric cancer
Part 1 Phase 2 data due 1H 2019.
ASLAN002
Acute Myeloid Leukemia (AML)
Phase 1/2 new data presented at at ASCO Gastrointestinal Cancers Symposium January 2019.
Varlitinib + gemcitabine and cisplatin
Biliary tract cancer
Phase 1 first part of trial has been completed. Part 2 data due May 2019.
ASLAN004
Atopic dermatitis

Latest News

  1. Top Ranked Momentum Stocks to Buy for March 29th
  2. ASLAN Pharmaceuticals Completes First Part of Single Ascending Dose Study for ASLAN004 Targeting Atopic Dermatitis
  3. ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
  4. ASLAN Pharmaceuticals Signs New Agreement With Biogenetics for Commercialisation of ASLAN003 in South Korea
  5. ASLAN Pharmaceuticals to Partner With BioGenetics on Commercialisation of Varlitinib in South Korea
  6. ASLAN Pharmaceuticals Announces Strategic Prioritisation of Clinical Development Programs and Corporate Restructuring
  7. ASLAN Announces Publication of New Pre-Clinical Data Demonstrating the Activity of Varlitinib in TNBC Cell Lines
  8. ASLAN Pharmaceuticals to Present Positive varlitinib Data in First-Line Biliary Tract Cancer in Combination With Chemotherapy at ASCO GI
  9. ASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study
  10. ASLAN Pharmaceuticals Announces Study Results from Phase 2 Study of Varlitinib in First-line Gastric Cancer
  11. ASLAN Pharmaceuticals Announces IND Submission for ASLAN003 to U.S. FDA and Conclusion of 30-Day Review Period
  12. ASLAN Pharmaceuticals Completes Enrolment for Global Pivotal TreeTopp Study Ahead of Schedule
  13. New Data on ASLAN003 Presented at Ash Annual Meeting Shows First Signs of Clinical Activity of a DHODH Inhibitor in Acute Myeloid Leukaemia
  14. ASLAN Pharmaceuticals Announces Acceptance of Abstracts on New Varlitinib Data in BTC at ASCO Gastrointestinal Cancers Symposium
  15. Aslan Pharmaceuticals to Participate in 30th Annual Piper Jaffray Healthcare Conference
  16. ASLAN Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
  17. ASLAN Pharmaceuticals to Present New Data on ASLAN003 at American Society of Hematology Annual Meeting
  18. ASLAN Pharmaceuticals Appoints Robert E. Hoffman as Independent Director